Abstract:Abstract Purpose This study compares the efficacy and safety of lenvatinib and programmed cell death protein (PD)‐1 versus lenvatinib alone for advanced hepatocellular carcinoma (Ad‐HCC) refractory to hepatic arterial infusion chemotherapy (HAIC). Methods From April 2016 to September 2021, 145 patients with Ad‐HCC refractory to HAIC based on modified Response Evaluation Criteria in Solid Tumors criteria were enrolled by two radiologists and classified into the HAIC‐lenvatinib group (H‐L, n = 87) and HAIC‐lenvatinib‐PD‐1 group (H‐L‐P, n = 58). A propensity score‐matching method was used to reduce selective bias. The overall survival (OS) and postprogression‐free survival (PPS) rates were compared using the Kaplan–Meier method with log‐rank test. Multivariable analyses of independent prognostic factors were evaluated by means of the forward stepwise Cox regression model. Results After propensity score matching 1:1, the median OS was 43.6 months in the H‐L‐P group and was significantly longer than that (18.9 months) of the H‐L group ( p = .009). The median PPS was 35.6 months in the H‐L‐P group and was significantly longer than that (9.4 months) of the H‐L group ( p = .009). Multivariate analyses showed that the factors that ‎significantly affected the OS were‎ α‐fetoprotein (hazard ratio [HR], 2.14; 95% CI, 1.26–3.98; p = .006), early response to HAIC (HR, 0.44; 95% CI, 1.20–3.85; p = .009), and H‐L treatment (HR, ‎0.52; 95% CI, 0.30–0.86; p = .012). Modified albumin‐bilirubin grade (HR, 1.32; 95% CI, 1.03–1.70; p = .026), early response to HAIC (HR, 0.44; 95% CI, 0.25–0.77; p = .004), and H‐L (HR, ‎0.47‎; 95% CI, 0.28–0.78; p = .003) significantly affected the PPS. Conclusions This combination therapy of PD‐1 inhibitors plus lenvatinib has promising survival benefits in the management of patients with Ad‐HCC refractory to HAIC. Plain Language Summary Lenvatinib plus programmed death 1 inhibitor is an effective and safe postprogression treatment and improved significantly overall survival and postprogression‐free survival compared with lenvatinib alone in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.

Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed Death-1 inhibitors

Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study

Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization

HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study

Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein‐1 inhibitors: A promising treatment approach for high‐burden hepatocellular carcinoma

Hepatic Arterial Infusion Chemotherapy Combined with PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma

Hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib plus PD-1 inhibitors in hepatocellular carcinoma patients with tumor thrombosis in the inferior vena cava and/or right atrium

Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma

Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma

Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE

Addition of Immune Checkpoint Inhibitor Showed Better Efficacy for Infiltrative Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy and Lenvatinib: A Multicenter Retrospective Study

Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study

Efficacy and safety of HAIC alone vs. HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma

Postprogression treatment of lenvatinib plus PD‐1 inhibitor in advanced hepatocellular carcinoma refractory to HAIC

Comparison of Anti–pd-L1 with Anti–pd-1 Antibodies in the Combination of HAIC and Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.

Postprogression treatment of lenvatinib plus PD‐1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy

Comparing PD-L1 with PD-1 Antibodies Combined with Lenvatinib and Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma

Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma

172P Triple Combination Therapy of Lenvatinib, Toripalimab, and Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma

Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or Without Lenvatinib for Unresectable Hepatocellular Carcinoma